• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Avista Public Acquisition Corp. II

    11/2/23 4:39:07 PM ET
    $AHPA
    Get the next $AHPA alert in real time by email
    424B3 1 a424b3prospectussupplementa.htm 424B3 424(b)(3) Prospectus Supplement Cover - 8-K (New Director) Combined

    Filed Pursuant to Rule 424(b)(3)
    Registration No. 333-268613
     
    Prospectus Supplement No. 3
    (To Prospectus dated February 10, 2023)

    image_0.jpg
    OmniAb, Inc.
    image_1.jpg


    This prospectus supplement updates, amends and supplements the prospectus dated February 10, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-268613). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
    This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K (the “Current Report”), filed with the Securities and Exchange Commission on November 1, 2023, which is set forth below.
    This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
    Our Common Stock is listed on the Nasdaq Global Market under the symbol “OABI.” Our Warrants are listed on the Nasdaq Capital Market under the symbol “OABIW.” On November 1, 2023, the closing price of our Common Stock was $4.51 and the closing price for our Warrants was $0.68.
    image_1.jpg
    Our business and investment in our Common Stock and Warrants involve significant risks. These risks are described in the section titled “Risk Factors” beginning on page 10 of the Prospectus.
    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
    image_1.jpg
    The date of this prospectus supplement is November 2, 2023.

    |US-DOCS\146062233.1||


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ______________
    FORM 8-K
    ______________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): November 1, 2023

    OMNIAB, INC.
    (Exact Name of Registrant as Specified in Its Charter)
    Delaware001-4072098-1584818
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number)(I.R.S. Employer
    Identification No.)
    5980 Horton Street, Suite 600
    Emeryville
    CA94608
    (Address of principal executive offices)(Zip Code)
    (510) 250-7800
    (Registrant’s Telephone Number, Including Area Code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.0001 per shareOABIThe Nasdaq Global Market
    Warrants to purchase common stockOABIW
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☑
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    On November 1, 2023, the board of directors (the “Board”) of OmniAb, Inc. (the “Company”) appointed Steven Love as a member of the Board. The appointment was made based upon the recommendation of the Board’s nominating and corporate governance committee. In connection with his appointment to the Board, Mr. Love was also appointed to be a member and Chair of the Audit Committee of the Board and to be a member of the Human Capital Management and Compensation Committee of the Board.
    Mr. Love, 54, has served as the Chief Financial Officer of Heap Inc., a global SaaS product analytics company, since September 2021. Prior to joining Heap Inc., Mr. Love served as Chief Financial Officer at Juniper Square, Inc., a SaaS private investor platform, from March 2020 to September 2021. From November 2016 to February 2020, he served as Chief Financial Officer at Dialpad, Inc., a global SaaS communications company. Before Dialpad, he served as Chief Financial Officer at multiple other companies, including Mblox Inc., a global mobile messaging SaaS company (acquired by CLX Communications AB, now Sinch AB, in July 2016) and Evolv, Inc., a predictive analytic SaaS company (acquired by Cornerstone OnDemand Inc in November 2014). Mr. Love has also served as Vice President, Finance at Affymax, Inc. (Nasdaq: AFFY), a publicly-traded biotechnology company and as Vice President, Finance and Administration for Connetics Corporation, a publicly-traded specialty pharmaceutical company, among other roles. Mr. Love currently serves on the board of advisors for Puzzle Financial Inc., a privately held SaaS accounting platform, and as Chief Executive Officer Advisor to Peak Ventures Group, LLC, a privately held customer acquisition and monetization platform. Mr. Love holds B.S. and M.A. degrees in accounting from the University of Southern California and is a certified public accountant (inactive).
    In connection with his appointment to the Board, pursuant to the Company’s director compensation and stock ownership policy, Mr. Love has been granted restricted stock units representing 40,000 shares of the Company’s common stock and options to purchase 80,000 shares of the Company’s common stock. The options have an exercise price per share equal to the fair market value of the Company’s common stock on the date of grant. The foregoing awards will vest in three equal annual installments on each of the first three anniversaries following the date of grant. Mr. Love will also receive cash compensation for his service on the Board and committees thereof in accordance with the Company’s director compensation and stock ownership policy, as such policy may be amended from time to time. Mr. Love has entered into the Company’s standard form of indemnification agreement, the form of which has been filed with the Company’s most recent annual report on Form 10-K.
    There are no arrangements or understandings between Mr. Love and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Mr. Love has a material interest subject to disclosure under Item 404(a) of Regulation S-K. The Board has determined that Mr. Love is an independent director in accordance with The Nasdaq Stock Market LLC Listing Rules.
        





    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    OmniAb, Inc.
    Date: November 1, 2023By:/s/ Charles S. Berkman
    Name:Charles S. Berkman
    Title:Chief Legal Officer and Secretary



    Get the next $AHPA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AHPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AHPA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Avista Public Acquisition Corp. II

      EFFECT - OmniAb, Inc. (0001846253) (Filer)

      12/19/23 12:15:27 AM ET
      $AHPA
    • SEC Form EFFECT filed by Avista Public Acquisition Corp. II

      EFFECT - OmniAb, Inc. (0001846253) (Filer)

      12/19/23 12:15:16 AM ET
      $AHPA
    • SEC Form POS AM filed by Avista Public Acquisition Corp. II

      POS AM - OmniAb, Inc. (0001846253) (Filer)

      12/8/23 5:09:26 PM ET
      $AHPA

    $AHPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Higgins John L converted options into 13,173 shares, increasing direct ownership by 0.56% to 2,352,625 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/31/24 7:58:15 PM ET
      $AHPA
    • Foehr Matthew W converted options into 33,173 shares and covered exercise/tax liability with 13,221 shares, increasing direct ownership by 0.75% to 2,665,394 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/3/24 5:42:40 PM ET
      $AHPA
    • Berkman Charles S converted options into 17,556 shares and covered exercise/tax liability with 7,195 shares, increasing direct ownership by 4% to 272,317 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/3/24 5:42:11 PM ET
      $AHPA

    $AHPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

      OmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of Omn

      11/15/22 7:00:00 AM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

      First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms

      10/26/22 8:00:00 AM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AHPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foehr Matthew W bought $1,010,000 worth of shares (200,000 units at $5.05), increasing direct ownership by 8% to 2,645,442 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      12/13/23 3:25:06 PM ET
      $AHPA
    • Foehr Matthew W bought $405,517 worth of shares (95,000 units at $4.27), increasing direct ownership by 4% to 2,427,919 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      11/13/23 8:00:05 AM ET
      $AHPA

    $AHPA
    Leadership Updates

    Live Leadership Updates

    See more
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AHPA
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2022 Financial Results

      Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

      8/8/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports First Quarter 2022 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

      5/4/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AHPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Avista Public Acquisition Corp. II (Amendment)

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      2/13/24 5:57:04 PM ET
      $AHPA
    • SEC Form SC 13G filed by Avista Public Acquisition Corp. II

      SC 13G - OmniAb, Inc. (0001846253) (Subject)

      1/29/24 3:26:24 PM ET
      $AHPA
    • SEC Form SC 13G/A filed by Avista Public Acquisition Corp. II (Amendment)

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      3/8/23 2:15:29 PM ET
      $AHPA